Monique Gadd1, Ganes Pranavan1,2, Laeeq Malik1,2. 1. Australian National University Medical School, Australian National University, Acton, Australia. 2. Department of Medical Oncology, The Canberra Hospital, Garran, Australia.
Abstract
BACKGROUND: Tyrosine-kinase inhibitor (TKI) drugs have been considered first line treatment for metastatic renal cell cancer (RCC) for over a decade. TKI-induced hypertension is a common adverse-event in patients treated for metastatic RCC. AIM: This study was aimed at investigating an association between TKI-induced hypertension and treatment outcomes for metastatic RCC patients. METHODS AND RESULTS: Retrospective data pertaining to patients with histologically or radiologically confirmed metastatic RCC treated with sunitinib, pazopanib, sorafenib, axitinib or cabozantinib between June 2012 and May 2019 were evaluated. Clinical information and serial blood pressure measurements were extracted from medical records for each patient. We compared objective response rate, progression-free survival (PFS), and 12-month survival between TKI-induced hypertension (TIH) and non-TIH groups using χ2 and Mann-Whitney tests. Out of 72 patients screened, 52 met study eligibility criteria. The median age at diagnosis was 61 years (range: 42-85 years) with a clear male predominance. The majority of patients had a history of nephrectomy with clear cell pathology. Almost all patients were on first-line TKI therapy with sunitinib or pazopanib. Median follow-up was 11 months. About half of patients developed TKI-induced hypertension (grade 2-3). In the TIH group 82% were commenced on an antihypertensive agent. Median PFS measured 30.5 weeks for TIH group compared to 22.2 weeks for non-TIH (P = .05). The 6 month and 12 month survival rates for TIH were 82% and 56%, respectively, as compared to 76% and 44% for non-TIH. CONCLUSION: The occurrence of TKI-induced hypertension was found to be a positive prognostic factor for progression in patients with metastatic RCC.
BACKGROUND: Tyrosine-kinase inhibitor (TKI) drugs have been considered first line treatment for metastatic renal cell cancer (RCC) for over a decade. TKI-induced hypertension is a common adverse-event in patients treated for metastatic RCC. AIM: This study was aimed at investigating an association between TKI-induced hypertension and treatment outcomes for metastatic RCCpatients. METHODS AND RESULTS: Retrospective data pertaining to patients with histologically or radiologically confirmed metastatic RCC treated with sunitinib, pazopanib, sorafenib, axitinib or cabozantinib between June 2012 and May 2019 were evaluated. Clinical information and serial blood pressure measurements were extracted from medical records for each patient. We compared objective response rate, progression-free survival (PFS), and 12-month survival between TKI-induced hypertension (TIH) and non-TIH groups using χ2 and Mann-Whitney tests. Out of 72 patients screened, 52 met study eligibility criteria. The median age at diagnosis was 61 years (range: 42-85 years) with a clear male predominance. The majority of patients had a history of nephrectomy with clear cell pathology. Almost all patients were on first-line TKI therapy with sunitinib or pazopanib. Median follow-up was 11 months. About half of patients developed TKI-induced hypertension (grade 2-3). In the TIH group 82% were commenced on an antihypertensive agent. Median PFS measured 30.5 weeks for TIH group compared to 22.2 weeks for non-TIH (P = .05). The 6 month and 12 month survival rates for TIH were 82% and 56%, respectively, as compared to 76% and 44% for non-TIH. CONCLUSION: The occurrence of TKI-induced hypertension was found to be a positive prognostic factor for progression in patients with metastatic RCC.
Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Kiran Gupta; Jeffrey D Miller; Jim Z Li; Mason W Russell; Claudie Charbonneau Journal: Cancer Treat Rev Date: 2008-03-04 Impact factor: 12.111
Authors: Umberto Capitanio; Karim Bensalah; Axel Bex; Stephen A Boorjian; Freddie Bray; Jonathan Coleman; John L Gore; Maxine Sun; Christopher Wood; Paul Russo Journal: Eur Urol Date: 2018-09-19 Impact factor: 20.096
Authors: Isabel José Dionísio de Sousa; Joana Ferreira; Joana Rodrigues; Nuno Bonito; Paula Jacinto; Mariela Marques; João Ribeiro; Ana Pais; Helena Gervásio Journal: ESMO Open Date: 2016-05-17
Authors: Grant D Stewart; Sarah J Welsh; Stephan Ursprung; Ferdia A Gallagher; James O Jones; Jacqui Shields; Christopher G Smith; Thomas J Mitchell; Anne Y Warren; Axel Bex; Ekaterini Boleti; Jade Carruthers; Tim Eisen; Kate Fife; Abdel Hamid; Alexander Laird; Steve Leung; Jahangeer Malik; Iosif A Mendichovszky; Faiz Mumtaz; Grenville Oades; Andrew N Priest; Antony C P Riddick; Balaji Venugopal; Michelle Welsh; Kathleen Riddle; Lisa E M Hopcroft; Robert J Jones Journal: Br J Cancer Date: 2022-06-23 Impact factor: 9.075